Larry Zhang

Senior Vice President

Mr. Zhang joined CASI in September 2018 as President of CASI (Beijing)Pharmaceuticals Co., Ltd., which is a subsidiary of CASI, and became Global President of CASI in September 2019. He was appointed as the Senior Vice President of CASI in September 2024. Mr. Zhang has more than 20 years of management experience in the field of healthcare and biopharmaceutical at Fortune 500 companies worldwide.

Prior to joining CASI, Mr. Zhang was Vice President, Head of Public Affairs and Corporate Responsibility at Novartis Group (China), focusing on the public affairs/public relations strategy, including initiating Novartis' China policy focusing on NMPA new drug approval reform, intellectual property protection, generic quality consistency evaluation and new regulations on biosimilars. From 2011 to 2016, he was Chief Executive Officer of Sandoz Pharmaceutical (China), a Novartis Company. Mr. Zhang has also held executive leadership roles with Bayer Healthcare and Baxter International Corporation in the U.S. and Asia Pacific.

He holds bachelor and master degrees in nuclear physics from University of Science & Technology of China, an MBA in marketing/finance from the University of California at Los Angeles (UCLA), and received Ph.D. training in political science from University of Utah.